Key result
Early chronic Chagas cardiomyopathy is associated with a downregulation of peripheral immune response genes, including those involved in antigen presentation and T cell activation, which are distinct from non-Chagas cardiomyopathies.
Why the study?
The mechanisms by which patients with Chagas disease progress to chronic Chagas cardiomyopathy and advanced heart failure are poorly understood.
Cross-Sectional (n=33)
Early chronic Chagas cardiomyopathy is characterized by distinct downregulation of peripheral immune response genes, which may serve as biomarkers for early disease progression.
May aid early biomarker development in Chagas cardiomyopathy; leaves open validation and prognostic utility in prospective studies.
Background: is a neglected disease that affects approximately 6 million individuals worldwide. Of those infected, 20-30% will go on to develop chronic Chagas cardiomyopathy (CCC), and many ultimately to advanced heart failure. The mechanisms by which this progression occurs are poorly understood. In this exploratory study, we sought to provide insight into the physiologic changes associated with the development of early CCC. Methods: We used RNA sequencing to analyse the gene expression changes in the peripheral blood of six patients with Chagas disease with early structural heart disease, four patients with Chagas disease without any signs or symptoms of disease, thirteen patients without Chagas disease with early structural heart disease, and ten patients without Chagas disease or signs of heart disease. Pathway analyses and immune cell deconvolution were employed to further elucidate the biological processes underlying early CCC development. Findings: Our analysis suggests that early CCC is associated with a downregulation of various peripheral immune response genes, including changes suggestive of reduced antigen presentation and T cell activation. Notably, these genes and processes appear to be distinct from those of non-Chagas cardiomyopathies. Interpretation: This work highlights the potential importance of the immune response in early CCC, providing insight into the early pathogenesis of this disease and how it may differ from other cardiomyopathies. The changes we have identified may serve as biomarkers of early CCC and could inform future longitudinal cohort studies of markers of disease progression and strategies for the treatment of CCC in its early stages. Funding: NIH, FONDECYT, IDSA, NSF.
No takes yet. Share an insight, caveat, or question.
Duque et al. (2025) conducted a cross-sectional in Early-stage chronic Chagas cardiomyopathy (n=33). Early-stage chronic Chagas cardiomyopathy vs. Indeterminate stage Chagas disease and non-Chagas cardiomyopathy was evaluated on Differentially expressed genes (DEGs) in peripheral blood. Early chronic Chagas cardiomyopathy is associated with a downregulation of peripheral immune response genes, including those involved in antigen presentation and T cell activation, which are distinct from non-Chagas cardiomyopathies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: